These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

162 related items for PubMed ID: 14871992

  • 21. Thrombospondin-1 plus irinotecan: a novel antiangiogenic-chemotherapeutic combination that inhibits the growth of advanced human colon tumor xenografts in mice.
    Allegrini G, Goulette FA, Darnowski JW, Calabresi P.
    Cancer Chemother Pharmacol; 2004 Mar; 53(3):261-6. PubMed ID: 14658007
    [Abstract] [Full Text] [Related]

  • 22. Studies of the efficacy and pharmacology of irinotecan against human colon tumor xenograft models.
    Zamboni WC, Stewart CF, Cheshire PJ, Richmond LB, Hanna SK, Luo X, Poquette C, McGovren JP, Houghton JA, Houghton PJ.
    Clin Cancer Res; 1998 Mar; 4(3):743-53. PubMed ID: 9533544
    [Abstract] [Full Text] [Related]

  • 23. Development and characterization of a model of liver metastasis using human colon cancer HCT-116 cells.
    Ishizu K, Sunose N, Yamazaki K, Tsuruo T, Sadahiro S, Makuuchi H, Yamori T.
    Biol Pharm Bull; 2007 Sep; 30(9):1779-83. PubMed ID: 17827739
    [Abstract] [Full Text] [Related]

  • 24. Enhanced antitumor activity of 6-hydroxymethylacylfulvene in combination with irinotecan and 5-fluorouracil in the HT29 human colon tumor xenograft model.
    Britten CD, Hilsenbeck SG, Eckhardt SG, Marty J, Mangold G, MacDonald JR, Rowinsky EK, Von Hoff DD, Weitman S.
    Cancer Res; 1999 Mar 01; 59(5):1049-53. PubMed ID: 10070962
    [Abstract] [Full Text] [Related]

  • 25. Enhanced antitumor activity of anti-epidermal growth factor receptor monoclonal antibody IMC-C225 in combination with irinotecan (CPT-11) against human colorectal tumor xenografts.
    Prewett MC, Hooper AT, Bassi R, Ellis LM, Waksal HW, Hicklin DJ.
    Clin Cancer Res; 2002 May 01; 8(5):994-1003. PubMed ID: 12006511
    [Abstract] [Full Text] [Related]

  • 26. Targeting FoxM1 by thiostrepton inhibits growth and induces apoptosis of laryngeal squamous cell carcinoma.
    Jiang L, Wu X, Wang P, Wen T, Yu C, Wei L, Chen H.
    J Cancer Res Clin Oncol; 2015 Jun 01; 141(6):971-81. PubMed ID: 25391371
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Antisense anti-MDM2 mixed-backbone oligonucleotides enhance therapeutic efficacy of topoisomerase I inhibitor irinotecan in nude mice bearing human cancer xenografts: In vivo activity and mechanisms.
    Wang H, Wang S, Nan L, Yu D, Agrawal S, Zhang R.
    Int J Oncol; 2002 Apr 01; 20(4):745-52. PubMed ID: 11894120
    [Abstract] [Full Text] [Related]

  • 31. Irinotecan versus infusional 5-fluorouracil: a phase III study in metastatic colorectal cancer following failure on first-line 5-fluorouracil. V302 Study Group.
    Van Cutsem E, Blijham GH.
    Semin Oncol; 1999 Feb 01; 26(1 Suppl 5):13-20. PubMed ID: 10213010
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. A risk-benefit assessment of irinotecan in solid tumours.
    Siu LL, Rowinsky EK.
    Drug Saf; 1998 Jun 01; 18(6):395-417. PubMed ID: 9638386
    [Abstract] [Full Text] [Related]

  • 35. [Second-line irinotecan chemotherapy in the treatment of metastatic colorectal cancers: phase III trials].
    Mitry E, Ducreux M, Rougier P.
    Bull Cancer; 1998 Dec 01; Spec No():38-42. PubMed ID: 9932083
    [Abstract] [Full Text] [Related]

  • 36. European experience with irinotecan plus fluorouracil/folinic acid or mitomycin.
    Khayat D, Gil-Delgado M, Antoine EC, Coeffic D, Benhammouda A, Grapin JP, Bastian G.
    Oncology (Williston Park); 1998 Aug 01; 12(8 Suppl 6):64-7. PubMed ID: 9726094
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.